# A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

> **NCT04762511** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Herpes Simplex

## Interventions

- **BIOLOGICAL:** Lower dose formulation of HSV vaccine (GSK4108771A)
- **BIOLOGICAL:** Low dose formulation of HSV vaccine (GSK4108771A)
- **BIOLOGICAL:** Medium dose formulation of HSV vaccine (GSK4108771A)
- **BIOLOGICAL:** High dose formulation of HSV vaccine (GSK4108771A)
- **DRUG:** Placebo (saline)

## Key facts

- **NCT ID:** NCT04762511
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-02
- **Primary completion:** 2021-05-26
- **Final completion:** 2021-05-26
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** To enable development of an enhanced version of the vaccine
- **Last updated:** 2021-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762511, "A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04762511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*